Company Overview and News
NEW YORK Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found.
NEW YORK (Reuters) - Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found.
NEW YORK: Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found.
U.S. stocks limped into the end of the first quarter with modest losses Thursday as the S&P 500 lost 0.2% while the Dow Jones Industrial Average gave up 0.18%. The Nasdaq Composite was able to cobble together a small gain on the day.
NEW YORK, March 31, 2016 /PRNewswire/ -- Did you know? - Zentiva, the generics business of the Sanofi Group, employs 6,000 people worldwide. - Jeff Watson is President, Global Generics at Apotex, the largest Canadian-owned pharmaceutical company. - Željko Dudi? is Director of Purchasing at Hemofarm, the leading generic pharmaceutical company in Serbia. - Beximco Pharmaceuticals, a leading manufacturer and exporter of medicines in Bangladesh, currently produces more than 300 generic medicines which are available in well over 500 different presentations.
Some of the major US biotech companies are currently embroiled in high-profile patent disputes, which have put revenue from their best-selling products at risk. A new patent decision crops up every other day, emphasizing the treacherous and murky nature of pharma patent law.
Last week, Amgen, Inc. (NASDAQ:AMGN) won a patent dispute against Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and development partner Sanofi SA (ADR) (NYSE:SNY) over the cholesterol-lowering drug class, PCSK-9 inhibitors. The conflicting parties scored approval for their respective PCSK9 drugs, Repatha and Praluent, within a month of each other last summer and have been fighting for market share ever since.
March 21 Valeant Pharmaceuticals International Inc , target of a securities investigation and under scrutiny for its pricing and accounting practices, said on Monday that its longtime chief executive officer was leaving just three weeks after returning from a medical leave.
Amgen, Inc. (NASDAQ:AMGN) scored its first victory, related to its patent infringement claim against Regeneron and development partner Sanofi, on Wednesday. A federal jury supported the validity of two Amgen patents associated with its newly launched cholesterol-lowering drug, Repatha. In October 2014, Amgen had launched a lawsuit against Regeneron/Sanofi to stop them from selling a rival drug, Praluent, on grounds that it infringed upon Repatha’s patents.
Relypsa Inc. (NASDAQ:RLYP) dropped as low as 10% in yesterday’s trade, and closed down 6.65% at $12.08. The decline followed the biotech’s SEC filing, which reported prescription data of its newly launched star drug, Veltassa, for the month of February. The stock has plunged nearly 16% in the past two days, compared to a 4.3% loss of the iShares NASDAQ Biotechnology Index (IBB).
A federal jury ruled in favor of Amgen Inc in its lawsuit accusing Sanofi SA and Regeneron Pharmaceuticals Inc of infringing patents for antibodies related to a cholesterol drug, the defendants said on Wednesday.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...